The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 22, 2025

Abstract Despite azvudine being prioritized for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, its effectiveness and safety remain inadequately substantiated in hospitalized SARS‐CoV‐2 infected patients with liver diseases. A retrospective nine‐center cohort study along an independent validation is conducted to examine efficacy (Clinical Trial Registration Number: NCT06349655). The primary outcome all‐cause mortality secondary composite disease progression. Efficacy assessed via Kaplan–Meier analysis Cox regression, subgroup sensitivity analyses further validation. Among 32 864 patients, 1022 eligible recipients, controls are included through propensity score match. reveals that associated a lower risk progression (both p <0.0001). regression suggests recipients could have 39% than (95% confidence interval [CI]: 0.468–0.795, <0.001), but no notable significance (hazard ratio: 0.85, 95% CI: 0.686‐1.061, = 0.154). Subgroup has greater benefit both kidney diseases or without autoimmune Three cohorts confirm robustness findings. Safety observes few adverse events recipients. Within 15 days after administration, significant difference function indexes observed between two groups except time points. These findings demonstrate shows potential clinical improving diseases, acceptable effects.

Language: Английский

Azvudine alleviates SARS-CoV-2-induced inflammation by targeting myeloperoxidase in NETosis

Chinese Chemical Letters, Journal Year: 2024, Volume and Issue: unknown, P. 110238 - 110238

Published: July 1, 2024

Language: Английский